Cargando…

Acetophenone protection against cisplatin-induced end-organ damage

Cisplatin is a widely used and efficacious chemotherapeutic agent for treating solid tumors, yet it causes systemic end-organ damage that is often irreversible and detrimental to quality of life. This includes severe sensorineural hearing loss, hepatotoxicity, and renal injury. Based on the hard-sof...

Descripción completa

Detalles Bibliográficos
Autores principales: Geohagen, Brian, Zeldin, Elizabeth, Reidy, Kimberly, Wang, Tao, Gavathiotis, Evripidis, Fishman, Yonatan I., LoPachin, Richard, Loeb, David M., Weiser, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723927/
https://www.ncbi.nlm.nih.gov/pubmed/36477009
http://dx.doi.org/10.1016/j.tranon.2022.101595
_version_ 1784844295461666816
author Geohagen, Brian
Zeldin, Elizabeth
Reidy, Kimberly
Wang, Tao
Gavathiotis, Evripidis
Fishman, Yonatan I.
LoPachin, Richard
Loeb, David M.
Weiser, Daniel A.
author_facet Geohagen, Brian
Zeldin, Elizabeth
Reidy, Kimberly
Wang, Tao
Gavathiotis, Evripidis
Fishman, Yonatan I.
LoPachin, Richard
Loeb, David M.
Weiser, Daniel A.
author_sort Geohagen, Brian
collection PubMed
description Cisplatin is a widely used and efficacious chemotherapeutic agent for treating solid tumors, yet it causes systemic end-organ damage that is often irreversible and detrimental to quality of life. This includes severe sensorineural hearing loss, hepatotoxicity, and renal injury. Based on the hard-soft acid-base theory, we recently developed two acetophenone-derived, enol-based compounds that directly interfere with the side effects of cisplatin. We investigated organ-specific and generalized toxicity in order to define dose-dependent responses in rodents injected with cisplatin with or without the protective compounds. All metrics that were used as indicators of toxicity showed retention of baseline or control measurements when animals were pre-treated with acetophenones prior to cisplatin administration, while animals injected with no protective compounds showed expected elevations in toxicity measurements or depressions in measurements of organ function. These data support the further investigation of novel acetophenone compounds for the prevention of cisplatin-induced end-organ toxicity.
format Online
Article
Text
id pubmed-9723927
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-97239272022-12-12 Acetophenone protection against cisplatin-induced end-organ damage Geohagen, Brian Zeldin, Elizabeth Reidy, Kimberly Wang, Tao Gavathiotis, Evripidis Fishman, Yonatan I. LoPachin, Richard Loeb, David M. Weiser, Daniel A. Transl Oncol Original Research Cisplatin is a widely used and efficacious chemotherapeutic agent for treating solid tumors, yet it causes systemic end-organ damage that is often irreversible and detrimental to quality of life. This includes severe sensorineural hearing loss, hepatotoxicity, and renal injury. Based on the hard-soft acid-base theory, we recently developed two acetophenone-derived, enol-based compounds that directly interfere with the side effects of cisplatin. We investigated organ-specific and generalized toxicity in order to define dose-dependent responses in rodents injected with cisplatin with or without the protective compounds. All metrics that were used as indicators of toxicity showed retention of baseline or control measurements when animals were pre-treated with acetophenones prior to cisplatin administration, while animals injected with no protective compounds showed expected elevations in toxicity measurements or depressions in measurements of organ function. These data support the further investigation of novel acetophenone compounds for the prevention of cisplatin-induced end-organ toxicity. Neoplasia Press 2022-12-05 /pmc/articles/PMC9723927/ /pubmed/36477009 http://dx.doi.org/10.1016/j.tranon.2022.101595 Text en © 2022 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Geohagen, Brian
Zeldin, Elizabeth
Reidy, Kimberly
Wang, Tao
Gavathiotis, Evripidis
Fishman, Yonatan I.
LoPachin, Richard
Loeb, David M.
Weiser, Daniel A.
Acetophenone protection against cisplatin-induced end-organ damage
title Acetophenone protection against cisplatin-induced end-organ damage
title_full Acetophenone protection against cisplatin-induced end-organ damage
title_fullStr Acetophenone protection against cisplatin-induced end-organ damage
title_full_unstemmed Acetophenone protection against cisplatin-induced end-organ damage
title_short Acetophenone protection against cisplatin-induced end-organ damage
title_sort acetophenone protection against cisplatin-induced end-organ damage
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723927/
https://www.ncbi.nlm.nih.gov/pubmed/36477009
http://dx.doi.org/10.1016/j.tranon.2022.101595
work_keys_str_mv AT geohagenbrian acetophenoneprotectionagainstcisplatininducedendorgandamage
AT zeldinelizabeth acetophenoneprotectionagainstcisplatininducedendorgandamage
AT reidykimberly acetophenoneprotectionagainstcisplatininducedendorgandamage
AT wangtao acetophenoneprotectionagainstcisplatininducedendorgandamage
AT gavathiotisevripidis acetophenoneprotectionagainstcisplatininducedendorgandamage
AT fishmanyonatani acetophenoneprotectionagainstcisplatininducedendorgandamage
AT lopachinrichard acetophenoneprotectionagainstcisplatininducedendorgandamage
AT loebdavidm acetophenoneprotectionagainstcisplatininducedendorgandamage
AT weiserdaniela acetophenoneprotectionagainstcisplatininducedendorgandamage